Solitary fibrous tumor

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC
| Solitary fibrous tumor | |
|---|---|
| Synonyms | SFT |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Often asymptomatic, but can include cough, chest pain, or dyspnea |
| Complications | Malignant transformation, metastasis |
| Onset | Typically in adulthood |
| Duration | Variable |
| Types | Benign, malignant |
| Causes | Unknown |
| Risks | Genetic mutations, environmental factors |
| Diagnosis | Histopathology, immunohistochemistry |
| Differential diagnosis | Hemangiopericytoma, mesothelioma, sarcoma |
| Prevention | None known |
| Treatment | Surgical resection, radiation therapy, chemotherapy |
| Medication | None specific |
| Prognosis | Generally good for benign tumors, variable for malignant |
| Frequency | Rare |
| Deaths | N/A |
Solitary Fibrous Tumor (SFT) is a rare type of tumor that can occur in any part of the body but is most commonly found in the pleura, which is the thin tissue surrounding the lung. Despite its name, solitary fibrous tumors can sometimes be multiple and can vary greatly in size and behavior. They were first described in the pleura but have since been identified in numerous extrapleural sites, including the meninges, peritoneum, liver, kidney, and orbit. The behavior of solitary fibrous tumors can range from benign to highly malignant.
Etiology and Pathogenesis[edit]
The exact cause of solitary fibrous tumors is unknown. They are considered to be of mesenchymal origin, arising from the connective tissue. Genetic studies have shown that the NAB2-STAT6 gene fusion is a frequent finding in SFTs, suggesting a role in the pathogenesis of these tumors.
Clinical Presentation[edit]
The symptoms of a solitary fibrous tumor can vary widely depending on its location. Many SFTs are asymptomatic and are discovered incidentally during imaging studies for unrelated reasons. When symptoms do occur, they are often related to the tumor compressing nearby structures. For example, an SFT in the thoracic cavity might cause shortness of breath, chest pain, or cough. An SFT in the central nervous system might present with headaches or neurological deficits.
Diagnosis[edit]
The diagnosis of a solitary fibrous tumor typically involves a combination of imaging studies and histopathological examination. Imaging techniques such as CT scans or MRI can help define the size and location of the tumor. However, a definitive diagnosis requires a biopsy of the tumor tissue, followed by microscopic examination and immunohistochemical staining. SFTs are typically positive for the CD34 antigen, BCL-2, and STAT6, the latter being particularly useful in confirming the diagnosis due to its association with the NAB2-STAT6 gene fusion.
Treatment[edit]
The treatment of choice for solitary fibrous tumors is surgical resection with the aim of complete removal. The feasibility and extent of surgery depend on the tumor's size, location, and relationship to surrounding structures. In cases where complete resection is not possible or the tumor is malignant, additional treatments such as radiation therapy or chemotherapy may be considered. The role of targeted therapy for SFTs is an area of ongoing research.
Prognosis[edit]
The prognosis for individuals with solitary fibrous tumors varies depending on several factors, including the size of the tumor, its location, and whether it is benign or malignant. Benign SFTs that are completely resected generally have an excellent prognosis with a low risk of recurrence. Malignant SFTs, however, can be aggressive and may metastasize to other parts of the body, leading to a poorer prognosis.
Epidemiology[edit]
Solitary fibrous tumors are rare, with an incidence that is difficult to determine due to their occurrence throughout the body and the broad range of differential diagnoses. They can occur at any age but are most commonly diagnosed in adults.
See Also[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
